Hepatic Encephalopathy: Contemporary Understanding and Clinical Advances

Dr Neeraj Manikath , Claude.ai

Abstract

Hepatic encephalopathy (HE) represents a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, affecting up to 80% of cirrhotic patients during disease progression. Recent advances in understanding ammonia metabolism, gut-brain-liver axis dysfunction, and neuroinflammation have transformed our therapeutic approach. This comprehensive review synthesizes current evidence on pathophysiology, diagnostic innovations, and emerging treatment strategies, with practical clinical pearls for intensivists managing this complex disorder.

Introduction

Hepatic encephalopathy remains a formidable challenge in critical care medicine, associated with significant morbidity, healthcare utilization, and mortality. The condition represents a continuum from minimal cognitive dysfunction to profound coma, with the spectrum now better understood through advanced neuroimaging and metabolomic studies. Despite being recognized for centuries, recent paradigm shifts in our understanding of HE pathogenesis have opened novel therapeutic avenues beyond traditional ammonia-lowering strategies.

Pathophysiological Advances: Beyond the Ammonia Hypothesis

The Multi-Hit Hypothesis

While ammonia remains central to HE pathogenesis, contemporary models emphasize a "multi-hit" mechanism involving:

1. Hyperammonemia and Astrocyte Dysfunction

Ammonia crosses the blood-brain barrier and is metabolized by astrocytes via glutamine synthetase
Glutamine accumulation leads to osmotic stress, astrocyte swelling, and altered neurotransmission
Recent studies demonstrate that ammonia induces mitochondrial dysfunction in astrocytes, impairing energy metabolism¹

2. Neuroinflammation

Systemic inflammation (from infections, spontaneous bacterial peritonitis) synergistically exacerbates ammonia neurotoxicity
Peripheral cytokines (IL-6, IL-1β, TNF-α) cross a disrupted blood-brain barrier
Microglial activation perpetuates central neuroinflammation²
This explains why HE often precipitates during infections even without significant changes in ammonia levels

3. Gut-Brain-Liver Axis Dysregulation

Intestinal dysbiosis with increased ammoniagenic bacteria (Enterobacteriaceae, Alcaligenes)
Decreased beneficial bacteria (Lachnospiraceae, Ruminococcaceae)
Increased intestinal permeability ("leaky gut") facilitating bacterial translocation
Bile acid dysmetabolism affecting neurosteroid synthesis³

4. Altered Neurotransmission

GABAergic tone enhancement through neurosteroid accumulation
Manganese deposition in basal ganglia causing parkinsonian features
Decreased dopaminergic and noradrenergic activity
Altered glutamate-glutamine cycling⁴

🔑 Clinical Pearl: The ammonia level paradox

Do not rely solely on venous ammonia levels for diagnosis or management decisions. Up to 10% of patients with clinical HE have normal ammonia levels, while some asymptomatic cirrhotics have elevated levels. Ammonia correlates poorly with HE severity. Use clinical assessment (West Haven Criteria, Stroop test) as your primary diagnostic tool, not biochemistry.

Classification: The 2022 ISHEN Consensus

The International Society for Hepatic Encephalopathy and Nitrogen Metabolism updated classification distinguishes:

Type A: Associated with acute liver failure Type B: Bypass-related (portosystemic shunting without intrinsic liver disease) Type C: Cirrhosis-associated

Within Type C:

Covert HE (previously Minimal HE + Grade 1): Subtle cognitive deficits detectable only by psychometric testing
Overt HE: Clinically apparent (West Haven Grades 2-4)
Recurrent HE: ≥2 episodes within 6 months
Persistent HE: Continuous cognitive impairment despite treatment⁵

🔑 Clinical Pearl: Covert HE matters

50-80% of cirrhotic patients have covert HE, which significantly impairs quality of life, driving ability, and fall risk. Screen your stable cirrhotic patients with simple bedside tools like the Animal Naming Test (<15 animals/minute suggests covert HE) or Stroop smartphone apps.

Diagnostic Innovations

Traditional Approaches Refined

West Haven Criteria remain the clinical gold standard:

Grade 0: No abnormality
Grade 1: Trivial lack of awareness, shortened attention span
Grade 2: Lethargy, disorientation, inappropriate behavior
Grade 3: Somnolent but arousable, gross disorientation, bizarre behavior
Grade 4: Coma

Limitations: Poor inter-rater reliability, especially distinguishing Grades 1-2

Novel Diagnostic Modalities

1. Critical Flicker Frequency (CFF)

Measures visual processing speed
Threshold <39 Hz indicates covert HE
Correlates with driving impairment
Limitations: Requires specialized equipment, affected by retinal disease⁶

2. Stroop Test Smartphone Applications

EncephalApp (free iOS/Android application)
Measures psychomotor speed and cognitive flexibility
Sensitivity 78%, specificity 90% for minimal HE
"Off" time >274.9 seconds diagnostic
Practical for outpatient screening⁷

3. Electroencephalography (EEG)

Shows characteristic triphasic waves in severe HE
Progressive slowing from alpha to theta/delta activity correlates with severity
Quantitative EEG may predict outcomes
Useful to exclude non-convulsive status epilepticus⁸

4. Advanced Neuroimaging

MRI: T1-weighted hyperintensity in globus pallidus (manganese deposition)
MR Spectroscopy: Elevated glutamine/glutamate peak, decreased myo-inositol and choline
Diffusion Tensor Imaging: White matter integrity changes
Research tools, not routine clinical practice⁹

🔑 Clinical Pearl: The ammonia sampling hack

If you must check ammonia (e.g., to confirm diagnosis in first episode), do it right:

Use arterial sample (10-15% higher, more accurate than venous)
Place on ice immediately
Analyze within 15 minutes (rises 5-10% per hour at room temperature)
Avoid hemolysis and prolonged tourniquet use
Early morning samples (diurnal variation exists)

Precipitating Factors: The HINGE Mnemonic

H - Hypovolemia/dehydration (excessive diuresis) I - Infection (SBP, pneumonia, UTI) - most common precipitant N - Nitrogenous load (GI bleeding, high protein diet, constipation) G - GABA-ergic medications (benzodiazepines, opioids)E - Electrolyte disturbances (hyponatremia, hypokalemia), Excess alcohol

Additional precipitants:

Hepatocellular carcinoma development
Portal vein thrombosis
TIPS procedure
Non-compliance with lactulose
Zinc deficiency

🔑 Clinical Pearl: Always hunt for precipitants

Spontaneous HE without precipitants is rare. In the ICU setting, systematically exclude:

Occult infection (diagnostic paracentesis for SBP even without typical features)
GI bleeding (check for melena, coffee-ground aspirate)
Medication review (recent sedatives, opioids added?)
Electrolyte panel (hyponatremia common and contributory)

Management: Evidence-Based Approaches

First-Line Therapy

1. Lactulose: Still the Gold Standard

Mechanism: Cathartic effect reduces colonic transit time; acidifies colon (pH 5-6) converting NH₃ to NH₄⁺ (non-absorbable); alters gut microbiota

Dosing strategy:

Acute overt HE: 20-30g (30-45mL) PO/NG q1-2h until bowel movement, then q6-8h
Target: 2-3 soft stools daily
Rectal administration: 300mL in 700mL water as retention enema if unable to take PO
Maintenance: Titrate to clinical response and bowel frequency¹⁰

Evidence: Meta-analysis of 29 RCTs showed lactulose reduces mortality (RR 0.59, 95% CI 0.40-0.87) and improves HE compared to placebo¹¹

🔑 Clinical Pearl: Lactulose titration art

The "2-3 stools/day" is a guide, not a rule. In critically ill patients:

Start aggressive (q2h dosing) for Grade 3-4 HE
Once mental status improves, prevent over-treatment diarrhea (causes dehydration/AKI/hypernatremia, worsening HE)
If no response after 24-48 hours at appropriate doses, reassess diagnosis and add rifaximin
Consider rectal lactulose for faster effect in obtunded patients

2. Rifaximin: The Game-Changer

Non-absorbable antibiotic targeting ammonia-producing gut bacteria

Dosing: 550mg PO BID (maintenance therapy)

Evidence:

RFHE trial (Bajaj 2011): Rifaximin + lactulose reduced HE recurrence from 46% to 22% (NNT=4) and hospitalizations by 50%¹²
Safe for long-term use (minimal resistance development)
Improves health-related quality of life
Cost-effective for recurrent HE despite high acquisition cost

Mechanism beyond antibacterial: Anti-inflammatory effects, modulates gut permeability, affects bile acid metabolism

🔑 Clinical Pearl: When to add rifaximin

First episode overt HE: Lactulose alone usually sufficient
Recurrent HE (≥2 episodes/6 months): Add rifaximin for secondary prophylaxis
Lactulose intolerance: Rifaximin monotherapy is acceptable alternative
Post-TIPS: Consider prophylaxis with rifaximin + lactulose
Covert HE with quality of life impairment: Consider rifaximin

Emerging and Adjunctive Therapies

3. L-Ornithine L-Aspartate (LOLA)

Mechanism: Substrate for ammonia detoxification via urea cycle (residual hepatocytes) and glutamine synthesis (muscle)

Dosing:

IV: 20-30g/day continuous infusion
Oral: 9-18g/day in divided doses

Evidence: Meta-analyses show benefit for overt and covert HE. European guidelines recommend as alternative/adjunct. Limited availability in some regions (including USA)¹³

4. Branched-Chain Amino Acids (BCAA)

Mechanism: Compete with aromatic amino acids for brain transport; ammonia detoxification in skeletal muscle

Evidence: Modest benefit in RCTs, particularly for covert HE and malnutrition. Not routinely recommended but consider in protein-intolerant patients¹⁴

5. Zinc Supplementation

Mechanism: Cofactor for urea cycle enzymes and glutamine synthetase

Dosing: 600mg zinc sulfate daily (or 220mg elemental zinc)

Evidence: 30-50% of cirrhotics are zinc deficient. Small RCTs show benefit. Consider in refractory HE or documented deficiency¹⁵

🔑 Clinical Pearl: The protein restriction myth

Stop restricting dietary protein! This outdated practice causes malnutrition and sarcopenia, worsening outcomes. Current evidence supports:

1.2-1.5 g/kg/day protein even during acute HE episodes
Plant-based proteins (legumes, nuts) may be superior to animal proteins
Small frequent meals (5-6/day) better than 3 large meals
Late-evening snack prevents overnight catabolism
Sarcopenia is a stronger predictor of mortality than HE itself¹⁶

Investigational Therapies: The Future

1. Fecal Microbiota Transplantation (FMT)

Rationale: Restore healthy gut microbiome

Evidence: Phase 2 RCT (Bajaj 2017) showed FMT improved cognition and reduced hospitalizations at 5 months. Larger trials ongoing¹⁷

2. Glycerol Phenylbutyrate

Mechanism: Ammonia scavenger (conjugates with glutamine, renally excreted as phenylacetylglutamine)

Evidence: Phase 2 RCT showed reduced HE events. Phase 3 trial (STOP-HE) failed primary endpoint but showed signal in subgroups. FDA approval pending¹⁸

3. Albumin Dialysis (MARS, Prometheus)

Evidence: May bridge to transplant in acute liver failure with refractory HE. No mortality benefit in cirrhosis. Expensive, limited availability¹⁹

4. Probiotics

Evidence: Multiple small RCTs with heterogeneous results. Meta-analysis suggests benefit for minimal HE. VSL#3, Lactobacillus most studied. Not currently recommended in guidelines but reasonable adjunct²⁰

5. Ornithine Phenylacetate

Ammonia scavenger under investigation. Early trials disappointing.

Special Populations and Scenarios

Acute Liver Failure with Grade 3-4 HE

Critical differences from cirrhotic HE:

1. Cerebral Edema Risk

Occurs in 50-80% of ALF with Grade 4 HE
Rare in chronic liver disease
Monitor with ICP monitoring (subdural/parenchymal) if Grade 3-4
Target ICP <20-25 mmHg, CPP >60 mmHg²¹

2. Management Modifications

Hypertonic saline (3%): Target Na 145-155 mEq/L
Therapeutic hypothermia (32-35°C): Reduces ammonia production and ICP
Mannitol: 0.5-1g/kg for ICP spikes (osmotic gap <20 mOsm)
Barbiturate coma: Refractory elevated ICP
Avoid hyperventilation (target PaCO₂ 35-40): Induces cerebral vasoconstriction worsening ischemia
Head elevation 30 degrees
Minimal stimulation, avoid hypotonic fluids²²

🔑 Clinical Pearl: When to intubate

Intubation thresholds in HE:

Grade 3: Consider for airway protection if unable to manage secretions
Grade 4: Intubate for airway protection and hyperventilation management
Pre-intubation: Avoid propofol (may worsen hypotension), prefer etomidate/ketamine
Post-intubation: Use propofol cautiously (may help with ICP), avoid excessive sedation impairing neuro exams

Post-TIPS Encephalopathy

Occurs in 20-50% of TIPS recipients
Risk factors: Age >65, pre-TIPS HE, hyponatremia, large stent diameter
Prevention: Consider 8mm stent rather than 10mm
TIPS reduction or embolization for refractory HE (50-70% response rate)²³

🔑 Clinical Pearl: TIPS and HE prevention

Prophylaxis strategy post-TIPS:

Start lactulose immediately post-procedure
Add rifaximin if high-risk (prior HE, age >65, MELD >15)
Screen for covert HE at 1 month with Stroop test
Discuss TIPS reduction early if overt HE develops (don't wait months)

Refractory Hepatic Encephalopathy

Defined as: Persistent HE despite optimal medical therapy (lactulose + rifaximin) for >1 month

Evaluation checklist:

Compliance verification (lactulose adherence?)
Precipitant identification (recurrent SBP, occult HCC?)
Large portosystemic shunts on imaging (consider TIPS reduction or shunt embolization)
Alternative diagnoses (Wernicke's, subdural hematoma, uremia, hyponatremia)
Zinc deficiency
Severe sarcopenia

Management escalation:

Add LOLA (if available)
Zinc supplementation
BCAA supplementation
FMT (investigational)
Interventional radiology shunt reduction
Liver transplant evaluation urgency²⁴

The Critical Care Perspective: ICU Management Nuances

Mechanical Ventilation Considerations

Avoid excessive sedation: Propofol reasonable at low doses; dexmedetomidine preferred (less ammonia accumulation)
Early awakening trials: Assess neurologic recovery
Nutritional support: Enteral nutrition 1.2-1.5g protein/kg via feeding tube
Continue lactulose via NGT (can titrate rectally if ileus)

Sepsis and HE: The Vicious Cycle

HE patients have impaired immunity (cirrhosis-associated immune dysfunction)
Infections precipitate HE; HE predicts infections
Low threshold for antibiotics in deteriorating HE
Always tap the ascites for cell count and culture
Consider empiric antibiotics if Grade 3-4 HE with SIRS criteria

Renal Replacement Therapy

Hepatorenal syndrome commonly coexists
CRRT preferred over IHD (hemodynamic stability, gradual ammonia/sodium correction)
Ammonia removal modest but may help refractory cases
Continue lactulose/rifaximin despite RRT

🔑 Clinical Pearl: The sodium conundrum in HE with hyponatremia

Hyponatremia (<130 mEq/L) is both:

A precipitant/exacerbator of HE
Common in cirrhosis with ascites

Management hack:

Correct slowly (4-6 mEq/L per 24h max) to avoid osmotic demyelination
Use hypertonic saline cautiously (may worsen ascites)
Volume restriction often ineffective and harmful (causes AKI)
Vaptans (tolvaptan) theoretically attractive but not proven beneficial and expensive
Albumin + midodrine + octreotide for HRS improves Na and outcomes

Prognostic Implications

Mortality Predictors

First episode overt HE: 1-year mortality 40-50%
HE is MELD-independent predictor of mortality
Grade 4 HE in cirrhosis: 30-day mortality ~80%
Recurrent HE: Median survival 12 months without transplant²⁵

Transplant Considerations

Overt HE: Automatic MELD exception points consideration
Recurrent/refractory HE: Indication for transplant evaluation
Post-transplant: HE resolves but neurocognitive deficits may persist

🔑 Clinical Pearl: Prognostic discussions with families

When counseling families about Grade 3-4 HE:

Frame as "brain failure from liver failure"
Reversibility depends on liver recovery potential
In cirrhosis without ALF, Grade 4 HE has poor prognosis without transplant
Discuss transplant candidacy early with hepatology
For non-transplant candidates, transitioning to comfort care is appropriate if refractory

Practical Oysters (Rare but Important Clinical Scenarios)

🦪 Oyster 1: Non-cirrhotic portal hypertension with HE

Consider congenital portosystemic shunts, extrahepatic portal vein obstruction. Imaging (CT/MRI angiography) reveals diagnosis. Shunt closure curative.

🦪 Oyster 2: Urea cycle disorders presenting as "HE"

Young patient, no liver disease, recurrent encephalopathy with protein loads, extremely high ammonia (>500 μmol/L). Obtain plasma amino acids, urine orotic acid. Requires genetic testing, specialized management.

🦪 Oyster 3: Valproate-induced hyperammonemic encephalopathy

Stupor/coma in patient on valproic acid (psychiatric or seizures). Ammonia elevated despite normal liver function. Stop valproate, L-carnitine supplementation reverses.

🦪 Oyster 4: Post-ureterosigmoidostomy hyperammonemia

Historic surgical procedure (bladder cancer). Colonic bacteria convert urea to ammonia, absorbed systemically. Treat with oral antibiotics, minimize urea load.

The 2024-2025 Paradigm Shifts: What's Truly New?

1. Microbiome as Therapeutic Target

Moving beyond rifaximin to personalized microbiome modulation. Ongoing trials of next-generation FMT, engineered probiotics, and microbiome-based diagnostics.

2. Sarcopenia Recognition

Muscle mass preservation now recognized as critical. Ammonia detoxification occurs primarily in skeletal muscle. Protein restriction abandoned; aggressive nutrition with exercise programs emerging.

3. Covert HE Screening

Growing recognition that subclinical HE impairs quality of life, driving safety, and predicts overt HE. Smartphone-based screening tools democratizing diagnosis.

4. Inflammation as Co-Target

Understanding that infections/inflammation synergize with ammonia shifted focus to early infection control and potential anti-inflammatory adjuncts.

5. Precision Medicine Approaches

Genomic, metabolomic, and microbiome profiling may enable personalized HE risk stratification and treatment selection in future.

Clinical Algorithm: ICU Approach to Grade 3-4 HE

Grade 3-4 HE Identified
         ↓
Assess Airway/Breathing (Intubate if Grade 4)
         ↓
Identify Precipitant (Labs, imaging, paracentesis)
         ↓
Start Lactulose 30mL q1-2h (rectal if NPO) + Rifaximin 550mg BID
         ↓
Treat Precipitant (Antibiotics for infection, blood transfusion, etc.)
         ↓
24-Hour Reassessment
         ↓
   Improving? ─YES→ Continue therapy, downgrade lactulose frequency
         ↓ NO
Compliance check, alternative diagnosis?
         ↓
Add LOLA, zinc if available
         ↓
Consider IR shunt embolization
         ↓
Transplant evaluation urgently
         ↓
Persistent Grade 4 × 72h without improvement
         ↓
Family meeting: Prognosis, goals of care, transplant candidacy

Key Takeaways for the Intensivist

HE is a clinical diagnosis; ammonia levels are unreliable guides
Always identify and treat precipitants – spontaneous HE is rare
Lactulose + rifaximin is the evidence-based foundation
Do not restrict protein – causes sarcopenia and worse outcomes
Grade 3-4 HE has high mortality without liver transplant in cirrhosis
Cerebral edema is a concern in ALF, not cirrhotic HE
Screen for covert HE in your stable cirrhotic patients
Think beyond ammonia: neuroinflammation and microbiome matter
Early transplant evaluation for recurrent/refractory HE
Individualize therapy – one size does not fit all

Conclusion

Hepatic encephalopathy remains a complex, multi-factorial syndrome requiring astute clinical assessment and individualized management. Recent advances have expanded our therapeutic armamentarium beyond traditional ammonia-lowering strategies to include microbiome modulation, nutritional optimization, and recognition of neuroinflammation. For the critical care physician, systematic precipitant identification, aggressive lactulose/rifaximin therapy, and early transplant consideration form the cornerstone of management. As our understanding of the gut-brain-liver axis deepens, personalized medicine approaches promise to transform HE care in the coming decade.

References

Bosoi CR, Rose CF. Identifying the direct effects of ammonia on the brain. Metab Brain Dis. 2009;24(1):95-102.
Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40(2):247-254.
Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303(6):G675-685.
Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2002;17(4):221-227.
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735.
Romero-Gómez M, Córdoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45(4):879-885.
Bajaj JS, Heeren TC, Acharya C, et al. Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2015;13(10):1828-1835.
Amodio P, Del Piccolo F, Pettenò E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35(1):37-45.
Gupta RK, Saraswat VA, Poptani H, et al. Magnetic resonance imaging and localized in vivo proton spectroscopy in patients with fulminant hepatic failure. Am J Gastroenterol. 1993;88(5):670-674.
Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046.
Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;(5):CD003044.
Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
Bai M, Yang Z, Qi X, Fan D, Han G. L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2013;28(5):783-792.
Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015;(9):CD001939.
Riggio O, Merli M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology. 1992;16(3):785-789.
Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43.
Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66(6):1727-1738.
Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59(3):1073-1083.
Bañares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57(3):1153-1162.
Xu J, Ma R, Chen LF, Zhao LJ, Chen K, Zhang RB. Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary Pancreat Dis Int. 2014;13(4):354-360.
Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007;35(11):2498-2508.
Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-1589.
Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103(11):2738-2746.
Neff G. Pharmacoeconomics of hepatic encephalopathy. Pharmacotherapy. 2010;30(5 Pt 2):28S-32S.
Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890-895.

Friday, October 17, 2025